Running in the family: A rare diagnosis of familial papillary thyroid cancer  by O’Connell, L. et al.
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INTRODUCTION:  Whilst  inherited  medullary  thyroid  cancer  has  been  extensively  reported,  familial  non-
medullary  thyroid  cancer  is a rare  and  less  well  described  clinical  entity.  Familial  forms  of  the  disease
demonstrate  more  aggressive  features  than  sporadic  non-medullary  thyroid  cancer.
PRESENTATION  OF CASE:  A  54  year  old  lady  was  referred  with  globus  on  a  background  of a longstanding
goitre.  Three  ﬁrst  degree  relatives  had  a history  of non-medullary  thyroid  carcinoma.  Investigations
revealed  a papillary  thyroid  carcinoma  and the  patient  proceeded  to  total thyroidectomy  and  ipsilateral
Level  VI  neck  dissection,  followed  by  adjuvant  radioiodine  ablation.
DISCUSSION:  Familial  papillary  thyroid  carcinoma  syndrome  is  deﬁned  as three  or  more  ﬁrst  degree
relatives  diagnosed  with  the disease  in  the  absence  of other  known  associated  syndromes.  It is  often
associated  with  the  presence  of benign  thyroid  disorders,  and is  characterised  by the  early  onset  of
multi-focal  bilateral  locally  advanced  tumours.
CONCLUSION:  Familial  papillary  thyroid  cancer  is  a  rare  clinical  entity  but  should  be considered  where
≥3  ﬁrst  degree  relatives  are  diagnosed  with  non-medullary  thyroid  cancer.  It is necessary  to exclude
other  familial  tumour  syndromes  to make  the  diagnosis.  It demonstrates  more  aggressive  features  with
higher rates  of  local  recurrence  than its sporadic  counterpart,  and  therefore  mandates  more  aggressive
management  than  might  otherwise  be  indicated.  Screening  of ﬁrst degree  relatives  should  be  considered.
SUMMARY:  The  case  of  a  54  year  old  female  diagnosed  with  familial  non-medullary  thyroid  carcinoma  is
reported.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Familial thyroid cancer is conventionally divided into either
edullary or non-medullary types [1]. Inherited medullary thyroid
ancer has been extensively reported, either in isolation or in the
etting of MEN2 syndrome.
In contrast, familial non-medullary thyroid cancer is a rare
nd less well described clinical entity [1]. It is a heterogeneous
isease incorporating both syndromic-associated tumours and
on-syndromic tumours [1]. The ﬁrst group encompasses familial
denomatous polyposis (FAP), PTEN-hamartoma syndrome (Cow-
en’s disease), Werner syndrome and the Carney complex, where
hyroid cancer is not the primary tumour [1]. The second group has
een deﬁned as the presence of three or more ﬁrst degree relatives
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reativecommons.org/licenses/by-nc-nd/4.0/).with a well differentiated thyroid cancer, in the absence of another
familial tumour syndrome [1]. The form of inheritance is believed to
be autosomal dominant with incomplete penetrance and variable
expression. Although only recently becoming elucidated, a number
of subtypes have been described associated with various gene loci;
these include pure familial papillary thyroid cancer, familial papil-
lary thyroid cancer with multinodular goitre, and papillary thyroid
cancer associated with renal papillary neoplasia [1].
Familial forms of the disease demonstrate more aggressive fea-
tures such as early onset, multi-focality, lymphatic and vascular
invasion with associated extra-thyroidal extension and exten-
sive lymph node metastatic disease when compared to sporadic
tumours [1–4]. Interestingly, it does not appear to be associated
with known BRAF mutations which occur in sporadic papillary
thyroid carcinoma. It is associated with a reduction in disease-
free survival although overall survival appears to be unaltered
[2,4,5]. Multi-modality treatment is advocated, encompassing a
total thyroidectomy and ipsilateral Level VI neck dissection as well
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Table  1
Syndromic FNMTC: inheritance and genetic loci [1].
Syndrome Histologic type Gene loci Gene mutation
FAP  PTC 5q21 APC tumour suppressor gene
Cowden syndrome FTC, PTC, C cell hyperplasia 10q23.2 PTEN tumour suppressor gene
Carney complex FTC, PTC 2p16, 17q22–24 PRKAR1-x
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RWerner syndrome FTC, PTC, ATC 
TC, papillary thyroid carcinoma. FTC, follicular thyroid carcinoma. ATC, anaplastic 
s radioactive iodine ablation and suppressive thyroid hormone
herapy [6].
There is no consensus regarding familial screening. A thyroid
ltrasound of unaffected adult relatives on an annual basis has been
ecommended by some authors while others suggest that routine
hysical examination in an outpatient setting is sufﬁcient [6].
This case is important because it raises awareness of a rare dis-
ase which is not commonly encountered in clinical practice. It
ncourages clinicians to consider familial papillary thyroid can-
er as a differential diagnosis when multiple family members are
ffected.
. Presentation of case
A 54 year old lady was referred complaining of an intermit-
ent choking sensation. She had no associated stridor, dyspnoea
r dysphagia. She had no clinical symptoms suggestive of hyper
r hypothyroidism. Her background history was signiﬁcant for the
resence of a longstanding goitre. Her medical history was  other-
ise non-contributory and she took no regular medications.
The patient reported that three ﬁrst degree relatives had a his-
ory of well differentiated thyroid carcinoma. Her mother was
iagnosed with thyroid carcinoma in her 30 s and underwent a total
hyroidectomy. Accurate histological diagnosis of her thyroid was
ot established. Her mother also underwent a right nephrectomy
or a renal cell carcinoma. Her sister was diagnosed with a papillary
hyroid carcinoma aged 38 years. She underwent a total thyroidec-
omy and adjuvant radioactive iodine ablation. She remains disease
ree 2 years later. She also underwent a left nephrectomy for a non-
unctioning kidney secondary to vesicoureteric reﬂux. Her second
ister was diagnosed aged 48 years and had a background history
f a multinodular goitre. She underwent a total thyroidectomy for a
apillary thyroid carcinoma and adjuvant radioactive iodine abla-
ion. She subsequently developed a local recurrence nine years after
er initial diagnosis and underwent further surgical resection. A
umber of other malignancies were diagnosed within the family
ut these were not consistent with any identiﬁable syndrome.
On examination she had a multi-nodular goitre with a dominant
odule on the right side with no associated lymphadenopathy. She
roceeded to have a thyroid ultrasound and FNAC of a 1.2 cm focal
odule with internal microcalciﬁcations. The resulting cytology
as reported as Thy 5, showing features consistent with papillary
hyroid carcinoma. Preoperative TFTs demonstrated a hypothyroid
icture with an elevated TSH (7.67) and decreased free T4 (10.8).
erology performed a number of years prior to referral showed a
egative anti-thyroglobulin antibody and an anti-microsomal anti-
ody titre of 6400.
able 2
on-syndromic FNMTC: inheritance and genetic loci [1].
Histologic type Inheritance 
PTC with papillary RCC Unknown 
Familial MNG with PTC Autosomal dominant
Familial PTC Unknown 
Familial thyroid carcinoma with oxyphilia Autosomal dominant
CC, renal cell carcinoma. MNG, multinodular goitre.8p11–p12 WRN
id cancer.
She proceeded to a total thyroidectomy and ipsilateral Level VI
central nodal dissection. The revised American Thyroid Association
guidelines recommend central neck dissection for patients with
papillary thyroid cancer (Level B) as a large proportion of patients
who are clinically and radiologically node negative may  harbour
occult regional LN metastases. Although she had a small tumour
we felt that her strong family history rendered her high risk. This
intervention lasted 2½ h, with no immediate post-operative com-
plications. She was discharged 3 days from admission. The ﬁnal
histology demonstrated a multi-focal papillary thyroid carcinoma
(8 mm  focus in the right lobe and a second 1 mm focus in the left
lobe) occurring on a background of Hashimoto’s thyroiditis. There
was no extra-thyroidal extension. Five Level VI lymph nodes were
benign (pT1a(m)N0M0). Following discussion at the multidisci-
plinary thyroid conference, she was  referred for consideration of
radioiodine ablation due to the multifocal nature of disease. How-
ever, due to her low risk status and a thyroglobulin of <0.1 it was
decided to omit this.
Initial follow up was at 2 weeks post discharge, and thereafter at
2, 3 and 6 month intervals. She suffered no long term complications
and required minimal titration of her levothyroxine dose. TFTs on
most recent review (22 months post op) were normal, with normal
calcium and PTH.
In light of the strong family history of disparate malignancies the
possibility of a familial tumour syndrome was  considered. How-
ever, with histology conﬁrmed in two ﬁrst-degree relatives, and
no distinct pattern of other malignancy consistent with a familial
tumour syndrome, the ﬁnal diagnosis of familial papillary thyroid
cancer was made.
No genetic testing was  undertaken due to the lack of a distinct
identiﬁable syndrome.
3. Discussion
The case for a familial disposition to non-medullary thyroid car-
cinoma has only recently emerged and therefore the literature is
limited. The ﬁrst case of familial follicular thyroid carcinoma was
reported in 1955, when identical twins in Kansas City underwent
a total thyroidectomy and radical neck dissection [7]. A further
description was found in 1975 when a 9 year old boy, with no prior
environmental exposure and his mother were diagnosed [8].
Familial papillary thyroid carcinoma syndrome is deﬁned as
when three or more ﬁrst degree relatives are diagnosed with the
disease in the absence of other known associated syndromes. Sta-
tistically when two members of a family are diagnosed this may
be as a result of sporadic tumours but when three or more mem-
bers of a kindred or where men  or children are involved is more
Gene loci Candidate genes
1q21 Unknown
 14q Unknown
2q21 Unknown
 19p13.2 Unknown/TCO/T1MM44
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uggestive of a familial disposition. It is often associated with the
resence of benign thyroid disorders, such as lymphocytic thyroidi-
is, multinodular hyperplasia and multiple adenomatous nodules
2,4,9,10].
It is characterised by the early onset of multi-focal bilateral
ocally advanced tumours. The identiﬁcation of even micro-
apillary tumours within this group is associated with a 71% risk of
ulti-focal disease, a 43% risk of vascular invasion and a 57% rate
f lymph node metastasis, all statistically signiﬁcantly higher than
n sporadic papillary micro-carcinoma [11]. Despite the presence
f adverse prognostic features, overall survival does not appear to
e affected. This may  be due to the fact that mortality from differ-
ntiated thyroid carcinoma remains low.
The role for screening remains controversial. It has been sug-
ested for individuals with two affected family members a clinical
istory, examination and cervical ultrasound should be performed.
owever, the literature remains limited due to the small number of
eported cases with short follow-up. This stems from the low preva-
ence of the disease and the difﬁculty in identifying appropriate
ases. As the underlying genetic mutation has not been identiﬁed,
idespread genetic testing is not available (Tables 1 and 2).
. Conclusion
Familial papillary thyroid cancer is a rare clinical entity, but
should be considered where three or more ﬁrst degree relatives
are diagnosed with non-medullary thyroid cancer.
It is necessary to exclude other familial tumour syndromes, where
non-medullary thyroid cancer is not the primary malignancy.
It is believed to be inherited in an autosomal dominant mode with
incomplete penetrance and variable expression.
Familial papillary thyroid cancer demonstrates more aggressive
features with higher rates of local recurrence than the sporadic
counterpart. Therefore it mandates more aggressive manage-
ment than might otherwise be indicated.
Screening of ﬁrst-degree relatives should be considered.
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